| Name | Title | Contact Details |
|---|
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy and chronic obstructive pulmonary disease. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics` specified development and commercialization participation rights.
Western Oncolytics is developing a new generation of oncolytic viral immunotherapies to help patients accross the globe beat cancer
Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis and cellular technologies serving customers in more than 130 countries. As the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction, we believe in the potential of blood to do even more for patients than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers. Originally established in 1964 as COBE Laboratories, today, nearly 7,000 associates around the world are deeply committed to our vision of working together for better lives and our promise to unlock the potential of blood and cells. One way we back these words is through our pledge to be a conscientious corporate citizen and conduct our business in a way that provides social, environmental and economic benefit. At Terumo Blood and Cell Technologies, discovery never stops. We share a passion for thinking in new and different ways and we are proud to support education and research through a variety of community involvement activities as well as by providing grants to advance treatment options for patients. We know the work we do matters and has the potential to fundamentally improve health care. We remain dedicated to ensuring the lifesaving gift of blood is available around the world and to meeting and exceeding the needs of our customers and the patients we ultimately serve.
ABI Inc is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lynxcom Partners LLC is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.